In contrast, in CLL high patients, the BTK signaling may not represent the main regulator of cell survival, and therefore the use of ibrutinib may not prove to be the most effective target therapy, at least as a single treatment. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.